Latest News and Press Releases

Helsinn closes financing agreement with BancaStato to support business objectives and growth New funding secured to expand the portfolio of late- and commercial-stage supportive care, oncology and...

Helsinn closes financing agreement with Oberland Capital Funding secured to expand the portfolio of late- and commercial-stage oncology and rare disease products through in-licensing or acquisitionDr...

Helsinn announces the appointment of Dr Melanie Rolli as Group Chief Executive Officer - Giorgio Calderari appointed Vice Chairman of the Board Lugano, Switzerland, January 9, 2023 - Helsinn Group...

Helsinn Launches Fully Integrated Targeted Therapy (FITT) Strategy and Announces Leadership and Structural Changes Strategy focuses on developing and commercializing a differentiated pipeline of...

Helsinn and Xediton sign exclusive license and distribution agreement for TRUSELTIQ™ (infigratinib) in Canada Lugano, Switzerland, and Mississauga, Ontario, 20 December 2021 – Helsinn Group...

Helsinn announces European Commission approval of the liquid formulation of AKYNZEO® (fosnetupitant/palonosetron) Lugano, Switzerland, December 2, 2021 – Helsinn Group, a fully integrated, global...

Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care, supported by Helsinn, awarded to Patrick Johnson, MD Lugano, Switzerland, June 24, 2021 – Helsinn, a Swiss Biopharmaceutical...

Lugano, Switzerland, April 29, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to announce the appointment of Dr. Mary Lynne...

Lugano, Switzerland, April 29, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to announce the appointment of Dr. Mary Lynne...

3B FUTURE HEALTH GP S.A.R.L. ANNOUNCES THE LAUNCH OF 3B FUTURE HEALTH FUND II Grand Duchy of Luxembourg, March 24th, 2021 3B FUTURE HEALTH GP S.a.r.l. is pleased to announce the launch of the...